Emerging oligonucleotides and gene editing therapies offer greater precision, long-term efficacy, and improved adherence in ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, ...

Nuravax Inc., a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced today that two oral presentations—the Phase 1 clinical results and ...

Phase 3 trials have demonstrated that enlicitide decanoate significantly reduces LDL cholesterol, showing strong potential as ...

Bhat: With the rapidly advancing landscape of IBD treatments and the increasing complexities of the health care system, integrating clinical pharmacists into IBD care teams offers substantial benefits ...

A total of 639,786 patients with hyperlipidemia died with a primary cause related with a CV outcome, for an overall age-adjusted mortality rate (AAMR) of 7.1 per 100,000.

A treatment for hyperlipidemia for mothers and newborns, which had been cut off due to worsening profitability in 2023, will ...

Pompe's disease is a lysosomal storage disorder caused by a genetic deficiency of GAA. The disease is associated with severe ...

A death certificate from the Los Angeles County Department of Public Health indicates 'Cheers' alum George Wendt died from ...

The role of hyperlipidemia as a risk factor for stroke is unclear. A new retrospective study has examined the relationship between a history of hyperlipidemia and MRI-defined white matter ...

A new study published in the journal of BMC Pharmacology and Toxicology showed that both fenofibrate and curcumin effectively ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.